In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Hub Controls
  • Demo Video
  • Upload Photo
  • Edit Company Profile
  • Add a Link
  • Update Fast Facts
  • Add Management Bios
  • Private Messages
  • Edit My Profile
  • View/Edit My Portfolio

Email Updates

Search
AGORACOM News Flash

MARKET PRESSURE = BUYING OPPORTUNITIES

As predicted on the AGORACOM Blog, it appears we are now moving into capitulation phase and a great opportunity to buy good small-caps that have been thrown out with the bathwater. 

Follow AGORACOM commentary on:

  George's Blog    Grandich Blog

AGORACOM Micro-Blog

Close
AlphaRx > Message
Generic_profile

Fact Sheet

Posted by: akshaya02 on February 05, 2008 10:05PM

Hi Agoracom;

According to the fact sheet, products ARX 212, 828, and 838 are listed as part of being part of robust pipeline, however, the fact sheet also states these products are not currently under development. I am confused as according to prior press releases at least 828 and 838 were under development. It would be nice for the company to provide a clear update on the status of the products. Is the company not working on these products because they did not work out or it is waiting for something. If they did not work out why are they listed on the fact sheet as being part of the robust pipeline?

Please ask the company to provide an update on the status of research activities.

Did You Know?

AGORACOM members with a rank of Treasurer and up can access Level II quotes for OTCBB companies

Log in to Recommend Up_g

0 members recommend this.

Post a Reply

Please login to reply to this message.

Subscribe to Rss Feed
Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote
Open alrx Stock Quote